| 1 |
34665271 | Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. | 2022 Jan |
3 |
| 2 |
35033885 | Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. | 2022 Feb 15 |
2 |
| 3 |
35140970 | Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement. | 2022 Feb |
1 |
| 4 |
35259456 | Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL). | 2022 May |
1 |
| 5 |
35532877 | FLT3-targeted treatment for acute myeloid leukemia. | 2022 May 9 |
1 |
| 6 |
32414851 | Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. | 2021 Apr 1 |
2 |
| 7 |
32513964 | Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment. | 2021 Feb |
1 |
| 8 |
33017662 | Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. | 2021 Feb |
2 |
| 9 |
33189657 | Corrigendum to "AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes" [Experimental Hematology 2017;45:36-44]. | 2021 Jan |
1 |
| 10 |
33242449 | Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors. | 2021 Jan |
1 |
| 11 |
33777220 | Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD+ acute myeloid leukemia cells. | 2021 May |
1 |
| 12 |
33781547 | Quizartinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: More Patients Make It to Transplant, but Are There Any Other Benefits? | 2021 Feb |
1 |
| 13 |
33799721 | Data-Driven Math Model of FLT3-ITD Acute Myeloid Leukemia Reveals Potential Therapeutic Targets. | 2021 Mar 11 |
2 |
| 14 |
33831397 | Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway. | 2021 Jun |
2 |
| 15 |
33832508 | Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib. | 2021 Apr 8 |
1 |
| 16 |
33853292 | A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. | 2021 Aug 1 |
3 |
| 17 |
33945602 | GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML. | 2021 Aug 12 |
2 |
| 18 |
34268710 | A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib. | 2021 Dec |
1 |
| 19 |
34298678 | Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. | 2021 Jul 10 |
2 |
| 20 |
34424108 | Safety of FLT3 inhibitors in patients with acute myeloid leukemia. | 2021 Sep |
1 |
| 21 |
34490088 | The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells. | 2021 |
6 |
| 22 |
34555701 | Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. | 2021 Dec |
2 |
| 23 |
34583130 | Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors. | 2021 Oct 15 |
1 |
| 24 |
34597366 | Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. | 2021 Dec 28 |
3 |
| 25 |
34835225 | Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8+ T Cells. | 2021 Nov 8 |
2 |
| 26 |
30931863 | Design and Synthesis of New Sulfonamides-Based Flt3 Inhibitors. | 2020 |
2 |
| 27 |
31778791 | FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia. | 2020 Jan |
2 |
| 28 |
31912423 | Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports. | 2020 Mar |
3 |
| 29 |
31919472 | FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. | 2020 Mar |
1 |
| 30 |
32021432 | Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date. | 2020 |
2 |
| 31 |
32109580 | The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. | 2020 May |
3 |
| 32 |
32134197 | Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. | 2020 Apr 7 |
2 |
| 33 |
32199135 | A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia. | 2020 May 1 |
1 |
| 34 |
32215183 | Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. | 2020 Mar 17 |
7 |
| 35 |
32378580 | [Genetic analysis and targeted therapy for acute myeloid leukemia]. | 2020 |
1 |
| 36 |
32396937 | Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. | 2020 Aug 27 |
1 |
| 37 |
32409689 | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. | 2020 Nov |
6 |
| 38 |
32598495 | Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia. | 2020 Dec |
3 |
| 39 |
32722211 | Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. | 2020 Jul 24 |
1 |
| 40 |
32722298 | Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. | 2020 Jul 24 |
4 |
| 41 |
32748108 | Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. | 2020 Sep |
1 |
| 42 |
32772726 | Quizartinib for the treatment of acute myeloid leukemia. | 2020 Dec |
2 |
| 43 |
33162511 | [Importance of gene mutation analysis as prognostic factor of acute myeloid leukemia]. | 2020 |
1 |
| 44 |
30553232 | Fms-like tyrosine kinase 3 is a key factor of male fertility. | 2019 Mar 1 |
3 |
| 45 |
30681373 | Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. | 2019 Mar |
3 |
| 46 |
30770553 | 8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia. | 2019 Feb 15 |
2 |
| 47 |
30898762 | Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. | 2019 Mar 26 |
2 |
| 48 |
30939008 | Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia. | 2019 Apr 25 |
2 |
| 49 |
30997851 | FLT3 inhibitor quizartinib (AC220). | 2019 Aug |
3 |
| 50 |
31114157 | Quizartinib (AC220): a promising option for acute myeloid leukemia. | 2019 |
5 |